A group of related diseases characterized by an unbalanced or disproportionate proliferation of immunoglobulin-producing cells, usually from a single clone. These cells frequently secrete a structurally homogeneous immunoglobulin (M-component) and/or an abnormal immunoglobulin.

Successful treatment of IgM paraproteinaemic neuropathy with fludarabine. (1/496)

OBJECTIVES: To evaluate the response of four patients with IgM paraproteinaemic neuropathy to a novel therapy-pulsed intravenous fludarabine. BACKGROUND: The peripheral neuropathy associated with IgM paraproteinaemia usually runs a chronic, slowly progressive course which may eventually cause severe disability. Treatment with conventional immunosuppressive regimens has been unsatisfactory. Fludarabine is a novel purine analogue which has recently been shown to be effective in low grade lymphoid malignancies. METHODS: Four patients were treated with IgM paraproteinaemic neuropathy with intravenous pulses of fludarabine. Two of the four patients had antibodies to MAG and characteristic widely spaced myelin on nerve biopsy and a third had characteristic widely spaced myelin only. The fourth had an endoneurial lymphocytic infiltrate on nerve biopsy and a diagnosis of Waldenstrom's macroglobulinaemia. RESULTS: In all cases subjective and objective clinical improvement occurred associated with a significant fall in the IgM paraprotein concentration in three cases. Neurophysiological parameters improved in the three patients examined. The treatment was well tolerated. All patients developed mild, reversible lymphopenia and 50% mild generalised myelosuppression, but there were no febrile episodes. CONCLUSION: Fludarabine should be considered as a possible treatment for patients with IgM MGUS paraproteinaemic neuropathy.  (+info)

Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. (2/496)

To assess whether the progression of plasma cell tumors is accompanied by angiogenesis and secretion of matrix-degrading enzymes, bone marrow biopsy specimens from 20 patients with monoclonal gammopathy of undetermined significance (MGUS), 18 patients with nonactive multiple myeloma (MM), and 26 patients with active MM were evaluated for their angiogenic potential and matrix-metalloproteinase (MMP) production. A fivefold increase of the factor VIII+ microvessel area was measured by a planimetric method of point counting in the bone marrow of patients with active MM as compared with nonactive MM and MGUS patients (P <.01). When serum-free conditioned media (CM) of plasma cells isolated from the bone marrow of each patient were tested in vivo for their angiogenic activity in the chick embryo chorioallantoic membrane (CAM) assay, the incidence of angiogenic samples was significantly higher (P <. 01) in the active MM group (76%) compared with nonactive MM (33%) and MGUS (20%) groups. Moreover, a linear correlation (P <.01) was found between the extent of vascularization of the bone marrow of a given patient and the angiogenic activity exerted in the CAM assay by the plasma cells isolated from the same bone marrow. In vitro, a significantly higher fraction of the plasma cell CM samples from the active MM group stimulated human umbilical vein endothelial cell (HUVEC) proliferation (53%, P <.01), migration (42%, P <.05), and/or monocyte chemotaxis (38%, P <.05) when compared with nonactive MM and MGUS groups (ranging between 5% and 15% of the samples). Also, immunoassay of plasma cell extracts showed significantly higher (P <. 01) levels of the angiogenic basic fibroblast growth factor (FGF)-2 in the active MM patients than in nonactive MM and MGUS patients (153 +/- 59, 23 +/- 17, and 31 +/- 18 pg FGF-2/100 micrograms of protein, respectively). Accordingly, neutralizing anti-FGF-2 antibody caused a significant inhibition (ranging from 54% to 68%) of the biological activity exerted on cultured endothelial cells and in the CAM assay by plasma cell CM samples from active MM patients. Finally, in situ hybridization of bone marrow plasma cells and gelatin-zymography of their CM showed that active MM patients express significantly higher (P <.01) levels of MMP-2 mRNA and protein when compared with nonactive MM and MGUS patients, whereas MMP-9 expression was similar in all groups. Taken together, these findings indicate that the progression of plasma cell tumors is accompanied by an increase of bone marrow neovascularization. This is paralleled by an increased angiogenic and invasive potential of bone marrow plasma cells, which is dependent, at least in part, by FGF-2 and MMP-2 production. Induction of angiogenesis and secretion of MMPs by plasma cells in active disease may play a role in their medullary and extramedullary dissemination, raising the hypothesis that angiostatic/anti-MMP agents may be used for therapy of MM.  (+info)

Evaluation of a particle-enhanced turbidimetric immunoassay for the measurement of immunoglobulin E in an ILab 900 analyzer. (3/496)

BACKGROUND: The measurement of immunoglobulin E (IgE) in serum is widely used in the diagnosis of allergic reactions and parasitic infections. We describe here a fully automated assay for human IgE suitable for routine application in a general chemistry analyzer. METHODS: We used an ILab 900 analyzer. This instrument automates a particle-enhanced immunoturbidimetric assay with an analysis time of 9 min. RESULTS: The assay was linear in the range 4-1000 kIU/L (r = 0.9998). The intra- and interassay CVs at 57, 235, and 434 kIU/L were <3.5% and <7.4%, respectively. The detection limit was 4 kIU/L. Hemoglobin (+info)

14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myelome. (4/496)

Clonal plasma cells in monoclonal gammopathy of undetermined significance (MGUS) have been shown to bear copy number chromosome changes. To extend our knowledge of MGUS to structural chromosomal abnormalities, we have performed fluorescence in situ hybridization experiments with probes directed to the 14q32 and 13q14 chromosomal regions in 100 patients with either MGUS or smoldering multiple myeloma (SMM). 14q32 abnormalities were observed in at least 46% of patients with MGUS/SMM, with these abnormalities being present in the majority of clonal plasma cells. Whereas t(11;14)(q13;q32) occurs in 15% of MGUS/SMM patients, an incidence similar to that of overt multiple myeloma (MM) patients, translocation t(4;14)(p16;q32) is observed in only 2% of these cases [P = 0.002 for difference with t(11;14)], as compared with 12% in MM patients (P = 0.013). Monoallelic deletions of the 13q14 region were found in 21% of patients, with two types of situations. In half of the evaluable patients, and especially in patients with SMM, the deletion is present in the majority of clonal plasma cells, as in MM, whereas in the other half of the evaluable patients (essentially in MGUS patients), it is observed in subclones only. These data enable us to elaborate a plasma cell oncogenesis model from MGUS to MM.  (+info)

Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myelome. (5/496)

Chromosomal abnormalities are present in most (if not all) patients with multiple myeloma (MM) and primary plasma cell leukemia (PCL). Furthermore, recent data have shown that numerical chromosomal changes are present in most individuals with monoclonal gammopathy of undetermined significance (MGUS). Epidemiological studies have shown that up to one third of MM may emerge from pre-existing MGUS. To clarify further possible stepwise chromosomal aberrations on a pathway between MGUS and MM, we have analyzed 158 patients with either MM or primary PCL and 19 individuals with MGUS using fluorescence in situ hybridization (FISH). Our FISH analyses were designed to detect illegitimate IGH rearrangements at 14q32 or monosomy 13. Whereas translocations involving the 14q32 region were observed with a similar incidence (60%) in both conditions, a significant difference was found in the incidence of monosomy 13 in MGUS versus MM or primary PCL. It was present in 40% of MM/PCL patients, but in only 4 of 19 MGUS individuals. Moreover, whereas monosomy 13 was found in the majority of plasma cells in MM, it was observed only in cell subpopulations in MGUS. It is noteworthy that, in a group of 20 patients with MM and a previous MGUS history, incidence of monosomy 13 was 70% versus 31% in MM patients without a known history of MGUS (P =.002). Thus, this study highlights monosomy 13 as correlated with the transformation of MGUS to overt MM and may define 2 groups of MM with possible different natural history and outcome, ie, post-MGUS MM with a very high incidence of monosomy 13 and de novo MM in which other genetic events might be involved. Serial analyses of individuals with MGUS will be needed to validate this model.  (+info)

Monoclonal gammopathy may disturb oestradiol measurement in the treatment and monitoring of in-vitro fertilization: case report. (6/496)

A 31 year old woman had her treatment for infertility by in-vitro fertilization (IVF) cancelled because a highly elevated serum concentration of oestradiol was detected, contrary to the clinical picture and that observed by vaginal ultrasound. The immunoassay for measuring oestradiol had been affected by circulating heterophilic antibodies in the form of an elevated immunoglobulin (Ig) G-kappa M component. This may often be associated with a haematological malignancy of lymphoid origin, but this patient had a benign monoclonal gammopathy. Monoclonal gammopathy has not been described in IVF patients previously, nor has monoclonal gammopathy been reported as a cause of erroneously elevated oestradiol concentration. This sort of interference in oestradiol analysis is probably very rare, but may lead to unnecessary cancellation of the treatment. A highly elevated oestradiol that is not in accordance with the clinical course may indicate heterophilic antibody interference, and the cause should always be investigated.  (+info)

Somatic mutations of the L12a gene in V-kappa(1) light chain deposition disease: potential effects on aberrant protein conformation and deposition. (7/496)

Light chain deposition disease (LCDD) and light chain amyloidosis (AL) are disorders of monoclonal immunoglobulin deposition in which normally soluble serum precursors form insoluble deposits in tissues. A common feature in both is the clonal proliferation of B-cells that produce pathogenic light chains. However, the deposits in LCDD differ from those in AL in that they are ultrastructurally granular rather than fibrillar and do not bind Congo red or colocalize with amyloid P component or apolipoprotein E. The reason(s) for their differences are unknown but are likely multifactorial and related to their protein conformation and their interaction with other molecules and tissue factors in the microenvironment. Knowledge of the primary structure of the light chains in LCDD is very limited. In the present study two new kappa(1) light chains from patients with LCDD are described and compared to seven other reported kappa-LCDD proteins. The N-terminal amino acid sequences of light chain GLA extracted from the renal biopsy and light chain CHO from myocardial tissue were each identical to the respective light chains isolated from the urines and to the V-region amino acid sequences translated from the cloned cDNAs obtained from bone marrow cells. The germline V-region sequences, determined from the genomic DNA in both and in MCM, a previously reported kappa(1) LCDD light chain, were identical and related to the L12a germline gene. The expressed light chains in all three exhibit amino acid substitutions that arise from somatic mutation and result in increased hydrophobicity with the potential for protein destabilization and disordered conformation.  (+info)

Blood dyscrasias in clozapine-treated patients in Italy. (8/496)

BACKGROUND AND OBJECTIVE: Clozapine is a dibenzodiazepine derivative that is more effective than standard neuroleptic drugs in refractory schizophrenic patients, but its introduction in some countries was delayed by its propensity to cause blood dyscrasias. However, over the last ten years, different reports have clearly demonstrated that agranulocytosis and neutropenia can be easily prevented by means of strict hematologic surveillance. This article reviews the results of the first five years of the Italian Clozapine Monitoring System (ICLOS). DESIGN AND METHODS: The hematologic parameters of 2,404 patients registered between 1995 and 1999 were collected in a central database, before the patients began clozapine-treatment, weekly for the first 18 weeks, and then monthly throughout the duration of therapy. On the basis of conventional criteria, different risk levels have been identified with total leukocyte <3. 0x10(9)/L and/or an absolute neutrophil count <1.5x10(9)/L leading to immediate discontinuation of the drug. RESULTS: The analysis shows that 0.9% of the patients developed neutropenia and 0.7% agranulocytosis, mainly during the first 18 weeks of clozapine treatment. Drug discontinuation led to the normalization of hematologic parameters in all cases, and the use of growth factors reduced the risk of infectious complications. Transient leukocytosis and eosinophilia were also observed but these did not have any serious clinical effects. INTERPRETATION AND CONCLUSIONS: The ICLOS study confirms that regular hematologic monitoring is highly effective in minimizing the incidence of clozapine-associated blood dyscrasias. The lower than initially expected rates of agranulocytosis and associated deaths are encouraging in view of the benefits of this drug in treatment-resistant schizophrenia and other neurologic disorders.  (+info)

Paraproteinemias refer to the presence of abnormal levels of paraproteins in the blood. Paraproteins are immunoglobulins (antibodies) produced by plasma cells, which are a type of white blood cell found in the bone marrow. In healthy individuals, paraproteins play a role in the immune system's response to infection and disease. However, in certain conditions, such as multiple myeloma, monoclonal gammopathy of undetermined significance (MGUS), and Waldenstrom macroglobulinemia, plasma cells produce excessive amounts of a single type of paraprotein, leading to its accumulation in the blood.

Paraproteinemias can cause various symptoms depending on the level of paraproteins present and their impact on organs and tissues. These symptoms may include fatigue, weakness, numbness or tingling in the extremities, bone pain, recurrent infections, and kidney problems. In some cases, paraproteinemias may not cause any symptoms and may only be detected during routine blood tests.

It is important to note that while paraproteinemias are often associated with plasma cell disorders, they can also occur in other conditions such as chronic inflammation or autoimmune diseases. Therefore, further testing and evaluation are necessary to determine the underlying cause of paraproteinemia and develop an appropriate treatment plan.

Glomerular Diseases Associated with Paraproteinemias". Clinical Journal of the American Society of Nephrology. 11 (12): 2260- ...
CIDP has been associated with diabetes mellitus, HIV infection, and paraproteinemias.[citation needed] Some variants of CIDP ...
It has also been associated with certain paraproteinemias such as IgG lambda paraproteinemia.[citation needed] List of ...
... disorders are a subclass of immunoproliferative disorders-along with hypergammaglobulinemia and paraproteinemias. Follicular ...
Examples include, hematological cancers like Monoclonal Gammopathies (paraproteinemias), which can have significant kidney ... paraproteinemias (Myeloma and Amyloidosis), electrolyte disorders associated with cancer, and more as discussed below. As ... cancer cells can cause AKI by infiltrating the kidney or by precipitating with in the tubules as seen in paraproteinemias. [ ...
Paraproteinemias may be categorized according to the type of monoclonal protein found in blood:[citation needed] Light chains ...
... paraproteinemias (amyloidosis, multiple myeloma) and metabolic diseases (diabetes, cystinosis). Structural abnormalities of the ...
... paraproteinemias MeSH C15.378.147.780.243 - cryoglobulinemia MeSH C15.378.147.780.490 - heavy chain disease MeSH C15.378. ...
... plasma protein metabolism 273.0 Polyclonal hypergammaglobulinemia 273.1 Monoclonal paraproteinemia 273.2 Other paraproteinemias ...
Study Keyword: Paraproteinemias. The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ... Study Keyword: Paraproteinemias. Efficacy and Safety of Nemtabrutinib in Participants With Hematologic Malignancies. March 7, ...
HPC-A collection from a patient with TEMPI syndrome was complicated by microcytic erythrocytosis, leading to RBC contamination and hemolysis in the product. Adequate HPCs were collected and the patient tolerated infusion without RBC depletion or washing. Our report highlights difficulties of HPC-A c …
Nephrotic syndrome is kidney disease with proteinuria, hypoalbuminemia, and edema. Nephrotic-range proteinuria is 3 grams per day or more.
Glomerular Diseases Associated with Paraproteinemias". Clinical Journal of the American Society of Nephrology. 11 (12): 2260- ...
Paraproteinemias. Blood Protein Disorders. Hematologic Diseases. Hemorrhagic Disorders. Lymphoproliferative Disorders. ...
Paraproteinemias. *Immune System Diseases. *Plasma Cell Myeloma. *Hemostatic Disorders. *Hematologic Diseases. *Vascular ...
273.2 Other paraproteinemias convert 273.2 to ICD-10-CM. *. 273.3 Macroglobulinemia convert 273.3 to ICD-10-CM ...
Acidosis suggests renal tubular acidosis types I or II, or Fanconi syndrome (as is observed with paraproteinemias, amphotericin ...
... secondary to malignant or inflammatory disease 273.2 Other paraproteinemias Cryoglobulinemic: purpura vasculitis Mixed ...
Powered by Pure, Scopus & Elsevier Fingerprint Engine™ © 2023 Elsevier B.V. We use cookies to help provide and enhance our service and tailor content. By continuing you agree to the use of cookies. ...
Dysproteinemias; Monoclonal Gammopathy; Paraproteinemias; Plasma Cell Dyscrasias). By James R. Berenson , MD, Institute for ...
Cell Dyscrasia, Plasma -- See Paraproteinemias A group of related diseases characterized by an unbalanced or disproportionate ... Cell Dyscrasias, Plasma -- See Paraproteinemias A group of related diseases characterized by an unbalanced or disproportionate ...
Khalifeh, M., Goldfarb, D. G., Zeig-Owens, R., Todd, A. C., Shapiro, M. Z., Carwile, M., Dasaro, C. R., Li, J., Yung, J., Farfel, M. R., Brackbill, R. M., Cone, J. E., Qiao, B., Schymura, M. J., Prezant, D. J., Hall, C. & Boffetta, P., Dec 2023, In: American Journal of Industrial Medicine. 66, 12, p. 1048-1055 8 p.. Research output: Contribution to journal › Article › peer-review ...
Hollins, L. Claire (Recipient), Nisnevitch-Savarese, Zoulfira (Recipient), Read, Selina (Recipient), Rossi, John (Recipient), Royo, Marc (Recipient), Sarraf, Elie (Recipient), Shah, Bunty (Recipient), Moldovan, George-Lucian (Recipient), van Riggelen, Jan (Recipient), Shantz, Lisa (Recipient), Yengo, Christopher (Recipient), Booth, Jennifer (Recipient), Bates, Erica (Recipient), Schuster, Angel (Recipient), Clebak, Karl (Recipient), Daniels, Eldra W. (Recipient), Hays, Amy (Recipient), Hemerly, Nathan (Recipient), Thompson, Andrew (Recipient), George, Daniel (Recipient), Evey, Loren (Recipient), McLaughlin, Patricia (Recipient), Acharya, Jayant (Recipient), De Jesus, Sol (Recipient), OLeary, Amber (Recipient), Wright, Tonya (Recipient), Cantore, William (Recipient), Pantanelli, Seth (Recipient), Millard, Roberta (Recipient), Updegrove, Gary F. (Recipient), Choi, Karen (Recipient), Darowish, Charles (Recipient), Dooley, Amy (Recipient), Hackman, Nicole (Recipient), Krawiec, Conrad (Recipient), ...
Paraproteinemias Medicine & Life Sciences 100% * Survival Medicine & Life Sciences 44% * Diphosphonates Medicine & Life ...
Paraproteinemias are a group of disorders characterized by the presence of an abnormal amount of one or more paraproteins in ... Paraproteinemias are a group of disorders characterized by the presence of abnormal levels of one or more paraproteins (also ... Paraproteinemias can cause a variety of symptoms, depending on the type and severity of the disorder. Some common symptoms ... Treatment for paraproteinemias depends on the specific type and severity of the disorder, and may include chemotherapy, ...
Paraproteinemias; Kidney Neoplasms; Purpura, Thrombocytopenic, Idiopathic. Details ...
The symptoms of paraproteinemias can vary depending on the type and severity of the disorder. Common symptoms include fatigue, ... There are several types of paraproteinemias, including:. 1. Multiple myeloma: This is a type of cancer that affects the plasma ... Treatment options for paraproteinemias depend on the specific type of disorder and may include chemotherapy, radiation therapy ... CryoglobulinsCryoglobulinemiaParaproteinemiasRheumatoid FactorComplement Activating EnzymesAntigen-Antibody ComplexVasculitis, ...
Xochelli, A., Baliakas, P., Kavakiotis, I., Agathangelidis, A., Sutton, L. A., Minga, E., Ntoufa, S., Tausch, E., Yan, X. J., Shanafelt, T., Plevova, K., Boudjogra, M., Rossi, D., Davis, Z., Navarro, A., Sandberg, Y., Vojdeman, F. J., Scarfo, L., Stavroyianni, N., Sudarikov, A., & 42 othersVeronese, S., Tzenou, T., Karan-Djurasevic, T., Catherwood, M., Kienle, D., Chatzouli, M., Facco, M., Bahlo, J., Pott, C., Pedersen, L. B., Mansouri, L., Smedby, K. E., Chu, C. C., Giudicelli, V., Lefranc, M. P., Panagiotidis, P., Juliusson, G., Anagnostopoulos, A., Vlahavas, I., Antic, D., Trentin, L., Montillo, M., Niemann, C., Dohner, H., Langerak, A. W., Pospisilova, S., Hallek, M., Campo, E., Chiorazzi, N., Maglaveras, N., Oscier, D., Gaidano, G., Jelinek, D. F., Stilgenbauer, S., Chouvarda, I., Darzentas, N., Belessi, C., Davi, F., Hadzidimitriou, A., Rosenquist, R., Ghia, P. & Stamatopoulos, K., Sep 1 2017, In: Clinical Cancer Research. 23, 17, p. 5292-5301 10 p.. Research output: Contribution to ...
Paraproteinemias 93% * von Willebrand Factor 66% * Monoclonal Gammopathy of Undetermined Significance 21% ...
Dumontet, C., Demangel, D., Galia, P., Karlin, L., Roche, L., Fauvernier, M., Golfier, C., Laude, M. C., Leleu, X., Rodon, P., Roussel, M., Azaïs, I., Doyen, C., Slama, B., Manier, S., Decaux, O., Pertesi, M., Beaumont, M., Caillot, D., Boyle, E. M., & 19 othersCliquennois, M., Cony-Makhoul, P., Doncker, A. V., Dorvaux, V., Petillon, M. O., Fontan, J., Hivert, B., Leduc, I., Leyronnas, C., Macro, M., Maigre, M., Mariette, C., Mineur, P., Rigaudeau, S., Royer, B., Vincent, L., Mckay, J., Perrial, E. & Garderet, L., 2023 Feb, In: American Journal of Hematology. 98, 2, p. 264-271 8 p.. Research output: Contribution to journal › Article › peer-review ...
Paraproteinemias (1) * Autoanticuerpos (1) * Temblor (1) * Catatonia (1) * Enfermedades Desmielinizantes (1) * Trastornos de la ...
The laboratory forms part of the medical tuition offered by the Medicine and Pharmacy Faculty of the VUB. The Laboratory Index provides a list of possible exams with their technical specifications, instructions for their application, the degree of urgency, the minimum response time and/or the periodicity of application ...
Dive into the research topics where Center for Translational Research in Hematological Malignancies is active. These topic labels come from the works of this organizations members. Together they form a unique fingerprint ...
Heinze, K., Nazeran, T. M., Lee, S., Krämer, P., Cairns, E. S., Chiu, D. S., Leung, S. C. Y., Kang, E. Y., Meagher, N. S., Kennedy, C. J., Boros, J., Kommoss, F., Vollert, H. W., Heitz, F., du Bois, A., Harter, P., Grube, M., Kraemer, B., Staebler, A., Kommoss, F. K. F., & 62 othersHeublein, S., Sinn, H. P., Singh, N., Laslavic, A., Elishaev, E., Olawaiye, A., Moysich, K., Modugno, F., Sharma, R., Brand, A. H., Harnett, P. R., DeFazio, A., Fortner, R. T., Lubinski, J., Lener, M., Tołoczko-Grabarek, A., Cybulski, C., Gronwald, H., Gronwald, J., Coulson, P., El-Bahrawy, M. A., Jones, M. E., Schoemaker, M. J., Swerdlow, A. J., Gorringe, K. L., Campbell, I., Cook, L., Gayther, S. A., Carney, M. E., Shvetsov, Y. B., Hernandez, B. Y., Wilkens, L. R., Goodman, M. T., Mateoiu, C., Linder, A., Sundfeldt, K., Kelemen, L. E., Gentry-Maharaj, A., Widschwendter, M., Menon, U., Bolton, K. L., Alsop, J., Shah, M., Jimenez-Linan, M., Pharoah, P. D. P., Brenton, J. D., Cushing-Haugen, K. L., Harris, H. R., ...
Brastianos, P. K., Twohy, E. L., Gerstner, E. R., Kaufmann, T. J., Iafrate, A. J., Lennerz, J., Jeyapalan, S., Piccioni, D. E., Monga, V., Fadul, C. E., Schiff, D., Taylor, J. W., Chowdhary, S. A., Bettegowda, C., Ansstas, G., De La Fuente, M., Anderson, M. D., Shonka, N., Damek, D., Carrillo, J., & 25 othersKunschner-Ronan, L. J., Chaudhary, R., Jaeckle, K. A., Senecal, F. M., Kaley, T., Morrison, T., Thomas, A. A., Welch, M. R., Iwamoto, F., Cachia, D., Cohen, A. L., Vora, S., Knopp, M., Dunn, I. F., Kumthekar, P., Sarkaria, J., Geyer, S., Carrero, X. W., Martinez-Lage, M., Cahill, D. P., Brown, P. D., Giannini, C., Santagata, S., Barker, F. G. & Galanis, E., Jan 20 2023, In: Journal of Clinical Oncology. 41, 3, p. 618-628 11 p.. Research output: Contribution to journal › Article › peer-review ...
  • More specialized tests can be ordered to discover or link certain systemic diseases to kidney failure such as hepatitis b or hepatitis c, lupus serologies, paraproteinemias such as amyloidosis or multiple myeloma or various other systemic diseases that lead to kidney failure. (naod.us)
  • Paraproteinemias" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (jefferson.edu)
  • Paraprotein-Related Kidney Disease: Glomerular Diseases Associated with Paraproteinemias. (myeloma.org.uk)
  • This graph shows the total number of publications written about "Paraproteinemias" by people in this website by year, and whether "Paraproteinemias" was a major or minor topic of these publications. (jefferson.edu)
  • Since the start at the University of Utah I have initiated retrospective and prospective studies of the protein C system function in patients with paraproteinemias and myeloproliferative disorder. (uams.edu)
  • The clinical significance of diffuse normolipemic plane xanthomas is their association with paraproteinemias, most commonly multiple myeloma . (medscape.com)